Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 25 , ISSUE 7 ( July, 2021 ) > List of Articles

EDITORIAL

Therapeutic Options for the Treatment of Carbapenem-resistant Enterobacteriaceae Infections: Hope in the Times of Hype and Despair

Abdul S Ansari

Citation Information : Ansari AS. Therapeutic Options for the Treatment of Carbapenem-resistant Enterobacteriaceae Infections: Hope in the Times of Hype and Despair. Indian J Crit Care Med 2021; 25 (7):752-753.

DOI: 10.5005/jp-journals-10071-23918

License: CC BY-NC 4.0

Published Online: 07-07-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. www.who.int.
  2. www.cdc.gov.
  3. Ghanshani R, Gupta R, Gupta BS, Kalra S, Khedar RS, Sood S. Epidemiological study of prevalence, determinants, and outcomes of infections in medical ICU at a tertiary care hospital in India. Lung India 2015;32(5):441. DOI: 10.4103/0970-2113.164155.
  4. Ewans TM, Ortiz CR, LaForce FM. Prevention and control of nosocomial infection in the intensive care unit. In: Irwin RS, Cerra FB, Rippe JM, editors. Intensive care medicine. 4th ed. New York: Lippincot-Ravan, 1999, pp. 1074–1080.
  5. Ramasubramanian V, Porwal R, Rajesh N. Carbapenem resistant Gram-negative bacteremia in an Indian intensive care unit: a review of the clinical profile and treatment outcome of 50 patients. Indian J Crit Care Med 18(11):750–753. DOI: 10.4103/0972-5229.144021.
  6. Soman R, Veeraraghavan B, Hegde A, Jiandani P, Mehta Y, Nagavekar V, et al. Indian consensus on the management of CRE infection in critically ill patients (ICONIC)—India. Expert Rev Anti Infect Ther 2019;17(8):647–660. DOI: 10.1080/14787210.2019.1647103.
  7. Yamamoto M, Pop-Vicas AE. Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have? Crit Care 2014;18(3):229. DOI: 10.1186/cc13949.
  8. Anandan S, Damodaran S, Gopi R, Bakthavatchalam YD, Veeraraghavan B. Rapid screening for carbapenem resistant organisms: current results and future approaches. JCDR 2015;9(9):DM01. DOI: 10.7860/JCDR/2015/14246.6530.
  9. Veeraraghavan B, Shankar C, Karunasree S, Kumari S, Ravi R, Ralph R. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience. Pathog Glob Health 2017;111(5):240–246. DOI: 10.1080/20477724.2017.1340128.
  10. Kazi M, Khot R, Shetty A, Rodrigues C. Rapid detection of the commonly encountered carbapenemases (New Delhi metallo-ß-lactamase, OXA-48/181) directly from various clinical samples using multiplex real-time polymerase chain reaction assay. Indian J Med Microbiol 2018;36:369–375. DOI: 10.4103/ijmm.IJMM_18_324.
  11. Wangkheimayum J, Paul D, Dhar D, Nepram R, Chetri S, Bhowmik D, et al. Occurrence of acquired 16S rRNA methyltransferase-mediated aminoglycoside resistance in clinical isolates of Enterobacteriaceae within a tertiary referral hospital of Northeast India. Antimicrob Agents Chemother 2017;61(6):e01037. DOI: 10.1128/AAC.01037-16
  12. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis 2015;2:ofv050. DOI: 10.1093/ofid/ofv050.
  13. Ni W, Cai X, Wei C, Di X, Cui J, Wang R, et al. Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Braz J Infect Dis 2015;19:170–180. DOI: 10.1016/j.bjid.2014.12.004.
  14. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019;39(1):10–39. DOI: 10.1002/phar.2209.
  15. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh P-R, Viale P, Paño-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017;17:726–734. DOI: 10.1016/S1473-3099(17)30228-1.
  16. Shaw E, Rombauts A, Tubau F. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 2018;73(4):1104–1106. DOI: 10.1093/jac/dkx496.
  17. Marshall S, Hujer AM, Rojas LJ. Can ceftazidime-avibactam and aztreonam overcome ß-lactam resistance conferred by metallo-ß-lactamases in enterobacteriaceae? Antimicrob Agents Chemother 2017;61(4): e02243. DOI: 10.1128/AAC.02243-16.
  18. Karaiskos I, Galani I, Souli M. Novel ß-lactam-ß-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant gram-negative pathogens. Expert Opin Drug Metab Toxicol 2019;15(2):133–149. DOI: 10.1080/17425255.2019.1563071.
  19. Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae. Clin Infect Dis 2019;68(3):355–364. DOI: 10.1093/cid/ciy492.
  20. Rathish B, Wilson A, Warrier A, Prakash S, Babu R, Joy S. Clinical outcomes in carbapenem-resistant Enterobacteriaceae infections treated with ceftazidime-avibactam: a single-center observational study. Cureus 2021;13(2):e13081. DOI: 10.7759/cureus.13081.
  21. Nagvekar V, Shah A, Unadkat VP, Chavan A, Kohli R, Hodgar S, et al. Clinical Outcome of Patients on Ceftazidime-avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae. Indian J Crit Care Med 2021;25(7):780-784.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.